Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2024; 13(04): 274-280
DOI: 10.1055/s-0045-1802334
Review Article
Multimodality

Neoadjuvant Treatment in Rectal Cancer

Srinath Bhradwaj R.
1   Department of Medical Oncology, Apollo Cancer Institutes, Hyderabad, Telangana, India
,
Aditya Sarin
2   Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India
,
Shyam Aggarwal
2   Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India
,
Shikha Halder
3   Department of Radiation Oncology, Sir Ganga Ram Hospital, New Delhi, India
,
S. Hukku
4   Department of Radiation Oncology, BLK Max Hospital, New Delhi, India
,
Taha Mustafa
5   Department of Colo Rectal Surgery, Sir Ganga Ram Hospital, New Delhi, India
,
Vijay Arora
6   Department of Laparoscopic Surgery, Sir Ganga Ram Hospital, New Delhi, India
,
V.K. Malik
6   Department of Laparoscopic Surgery, Sir Ganga Ram Hospital, New Delhi, India
,
Shivendra Singh
7   Department of GI Oncosurgery, RGCI, New Delhi, India
,
G.V. Rao
8   Department of Gastrointestinal and Minimally Invasive Surgery, Asian Institute of Gastroenterology, Hyderabad, Telangana, India
,
Avinash Saklani
9   Department of Colorectal Surgery, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Rajesh Bhojwani
10   Department of Surgical Gastroenterology, Santokba Durlabhji Memorial Hospital, Jaipur, Rajasthan, India
,
Saumitra Rawat
11   Department of Surgical Gastroenterology, SGRH, New Delhi, India
,
C. Selvasekar
12   Clinical Services and Specialist Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom
,
Purvish M. Parikh
13   Department of Clinical Hematology, Sri Ram Cancer Center, Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

A major advance in rectal cancer was the evidence supporting short-course radiotherapy and long-course chemoradiotherapy. Both have been shown to improve local outcomes. Total neoadjuvant therapy (TNT) is the new kid on the block that provides further benefit of improving local responses as well as reducing systemic relapses, thus increasing overall survival. Details of the four key TNT trials are discussed. They pave the way for nonoperative management for patients who achieve clinical complete responses.

Keywords

TNT - NOM - LCCRT - SCRT


Publication History

Article published online:
28 January 2025

© 2025. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Jayne D, Pigazzi A, Marshall H. et al. Rectal cancer. JAMA 2017; 318 (16) 1569-1580
    CrossrefPubMedSearch in Google Scholar
  • 2 Indian Council of Medical Research. Three-year Report of Population Based Cancer Registries: 2012–2014. Accessed May 7, 2023 at: https://www.icmr.nic.in/sites/default/files/reports/PBCR_Report_2012-14.pdf
  • 3 Chandra M, Anand M, Khurana R. et al. Incidence and trends of colorectal cancer in India: an exploratory analysis. Indian J Cancer 2016; 53 (03) 401-406
    Search in Google Scholar
  • 4 Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1 (8496): 1479-1482
    CrossrefPubMedSearch in Google Scholar
  • 5 Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998; 133 (08) 894-899
    CrossrefPubMedSearch in Google Scholar
  • 6 Glynne-Jones R, Wyrwicz L, Tiret E. et al; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl. 04) iv263
    CrossrefPubMedSearch in Google Scholar
  • 7 Chand M, Bhangu A, Wotherspoon A. et al. EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. Ann Oncol 2014; 25 (04) 858-863
    CrossrefPubMedSearch in Google Scholar
  • 8 van Gijn W, Marijnen CA, Nagtegaal ID. et al; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12 (06) 575-582
    CrossrefPubMedSearch in Google Scholar
  • 9 Bosset JF, Collette L, Calais G. et al; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355 (11) 1114-1123
    CrossrefPubMedSearch in Google Scholar
  • 10 Sebag-Montefiore D, Stephens RJ, Steele R. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373 (9666): 811-820
    CrossrefPubMedSearch in Google Scholar
  • 11 Braendengen M, Tveit KM, Berglund A. et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008; 26 (22) 3687-3694
    CrossrefPubMedSearch in Google Scholar
  • 12 Song C, Zhang Y, Dong Y. et al. Efficacy and safety of neoadjuvant chemoradiotherapy with S-1 in locally advanced rectal cancer. J Gastrointest Oncol 2020; 11 (04) 639-646
    Search in Google Scholar
  • 13 Peeters KC, van de Velde CJ, Leer JW. et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients: a Dutch colorectal cancer group study. J Clin Oncol 2005; 23 (25) 6199-6206
    CrossrefPubMedSearch in Google Scholar
  • 14 Marijnen CA, van de Velde CJ, Putter H. et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005; 23 (09) 1847-1858
    CrossrefPubMedSearch in Google Scholar
  • 15 Ansari N, Solomon MJ, Fisher RJ. et al. Acute adverse events and postoperative complications in a randomized trial of preoperative short-course radiotherapy versus long-course chemoradiotherapy for t3 adenocarcinoma of the rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). Ann Surg 2017; 265 (05) 882-888
    CrossrefPubMedSearch in Google Scholar
  • 16 Cedermark B, Dahlberg M, Glimelius B, Påhlman L, Rutqvist LE, Wilking N. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336 (14) 980-987
    CrossrefPubMedSearch in Google Scholar
  • 17 Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93 (10) 1215-1223
    CrossrefPubMedSearch in Google Scholar
  • 18 Ciseł B, Pietrzak L, Michalski W. et al; Polish Colorectal Study Group. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol 2019; 30 (08) 1298-1303
    CrossrefPubMedSearch in Google Scholar
  • 19 Bujko K, Partycki M, Pietrzak L. Neoadjuvant radiotherapy (5 × 5 Gy): immediate versus delayed surgery. Recent Results Cancer Res 2014; 203: 171-187
    CrossrefPubMedSearch in Google Scholar
  • 20 Erlandsson J, Fuentes S, Radu C. et al. Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial. BJS Open 2021; 5 (06) 5
    CrossrefPubMedSearch in Google Scholar
  • 21 Habr-Gama A, Perez RO, Proscurshim I. et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006; 10 (10) 1319-1328 , discussion 1328–1329
    CrossrefPubMedSearch in Google Scholar
  • 22 García-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 2003; 46 (03) 298-304
    CrossrefPubMedSearch in Google Scholar
  • 23 Gérard JP, Conroy T, Bonnetain F. et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24 (28) 4620-4625
    CrossrefPubMedSearch in Google Scholar
  • 24 Bujko K, Nowacki MP, Nasierowska-Guttmejer A. et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72 (01) 15-24
    CrossrefPubMedSearch in Google Scholar
  • 25 Ma B, Ren Y, Chen Y. et al. Neoadjuvant therapy improves survival in rectal cancer patients with clinical T4M0 stage or pathological stage II/III: a meta-analysis. BMC Cancer 2020; 20 (01) 51
    PubMedSearch in Google Scholar
  • 26 Ngan SY, Burmeister B, Fisher RJ. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation for locally advanced rectal cancer. J Natl Cancer Inst 2012; 104 (24) 1821-1830
    Search in Google Scholar
  • 27 Erlandsson J, Holm T, Pettersson D. et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 2017; 18 (03) 336-346
    CrossrefPubMedSearch in Google Scholar
  • 28 Bhudia J, Glynne-Jones R. The evolving neoadjuvant treatment paradigm for patients with locoregional mismatch repair proficient rectal cancer. Curr Treat Options Oncol 2022; 23 (04) 453-473
    CrossrefPubMedSearch in Google Scholar
  • 29 Breugom AJ, Swets M, Bosset JF. et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015; 16 (02) 200-207
    CrossrefPubMedSearch in Google Scholar
  • 30 Conroy T, Bosset JF, Etienne PL. et al; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (05) 702-715
    CrossrefPubMedSearch in Google Scholar
  • 31 Jin J, Tang Y, Hu C. et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol 2022; 40 (15) 1681-1692
    CrossrefPubMedSearch in Google Scholar
  • 32 Bahadoer RR, Dijkstra EA, van Etten B. et al; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (01) 29-42
    CrossrefPubMedSearch in Google Scholar
  • 33 Dijkstra EA, Nilsson PJ, Hospers GAP. et al; Collaborative Investigators. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg 2023; 278 (04) e766-e772
    CrossrefPubMedSearch in Google Scholar
  • 34 Glynne-Jones R, Hollingshead J. TNT and local recurrence in the RAPIDO trial - untangling the puzzle. Nat Rev Clin Oncol 2023; 20 (06) 357-358
    CrossrefPubMedSearch in Google Scholar
  • 35 Verheij FS, Omer DM, Williams H. et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol 2024; 42 (05) 500-506
    CrossrefPubMedSearch in Google Scholar
  • 36 Schrag D, Shi Q, Weiser MR. et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med 2023; 389 (04) 322-334
    CrossrefPubMedSearch in Google Scholar
  • 37 Basch E, Dueck AC, Mitchell SA. et al. Patient-reported outcomes during and after treatment for locally advanced rectal cancer in the PROSPECT trial (alliance N1048). J Clin Oncol 2023; 41 (21) 3724-3734
    CrossrefPubMedSearch in Google Scholar
  • 38 Mei WJ, Wang XZ, Li YF. et al. Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): initial results of a phase III trial. Ann Surg 2023; 277 (04) 557-564
    CrossrefPubMedSearch in Google Scholar
  • 39 Deng Y, Chi P, Lan P. et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol 2016; 34 (27) 3300-3307
    CrossrefPubMedSearch in Google Scholar
  • 40 Deng Y, Chi P, Lan P. et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol 2019; 37 (34) 3223-3233
    CrossrefPubMedSearch in Google Scholar
  • 41 Calmels M, Labiad C, Lelong B. et al. Local excision after neoadjuvant chemoradiotherapy for mid and low rectal cancer: a multicentric French study from the GRECCAR group. Colorectal Dis 2023; 25 (10) 1973-1980
    CrossrefPubMedSearch in Google Scholar
  • 42 Bach SP, Gilbert A, Brock K. et al; TREC collaborators. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. Lancet Gastroenterol Hepatol 2021; 6 (02) 92-105
    CrossrefPubMedSearch in Google Scholar
  • 43 Bach SP. STAR-TREC Collaborative. Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC)? Protocol for the international, multicentre, rolling phase II/III partially randomized patient preference trial evaluating long-course concurrent chemoradiotherapy versus short-course radiotherapy organ preservation approaches. Colorectal Dis 2022; 24 (05) 639-651
    CrossrefPubMedSearch in Google Scholar
  • 44 Li X, Fu R, Ni H. et al. Effect of neoadjuvant therapy on the functional outcome of patients with rectal cancer: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol) 2023; 35 (02) e121-e134
    CrossrefPubMedSearch in Google Scholar
  • 45 Maas M, Beets-Tan RG, Lambregts DMJ. et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011; 29 (35) 4633-4640
    CrossrefPubMedSearch in Google Scholar
  • 46 Habr-Gama A, Perez RO, Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240 (04) 711-717 , discussion 717–718
    CrossrefPubMedSearch in Google Scholar
  • 47 Smith FM, Chang KH, Sheahan K, Hyland JM, O'Connell PR, Winter DC. The role of restaging imaging in predicting outcome after preoperative nonoperative therapy and rectal cancer. Int J Colorectal Dis 2013; 28 (04) 513-520
    Search in Google Scholar
  • 48 Bregendahl S, Emmertsen KJ, Lindegaard JC, Laurberg S. Urinary and sexual dysfunction in women after resection with and without preoperative radiotherapy for rectal cancer: a population-based cross-sectional study. Colorectal Dis 2015; 17 (01) 26-37
    CrossrefPubMedSearch in Google Scholar
  • 49 Croese AD, Lonie JM, Trollope AF, Vangaveti VN, Ho YH. A meta-analysis of the prevalence of low anterior resection syndrome and systematic review of risk factors. Int J Surg 2018; 56: 234-241
    CrossrefPubMedSearch in Google Scholar
  • 50 Karlsson L, Bock D, Asplund D, Ohlsson B, Rosenberg J, Angenete E. Urinary dysfunction in patients with rectal cancer: a prospective cohort study. Colorectal Dis 2020; 22 (01) 18-28
    CrossrefPubMedSearch in Google Scholar
  • 51 Bolton WS, Chapman SJ, Corrigan N. et al. The incidence of low anterior resection syndrome as assessed in an international randomized controlled trial (MRC/NIHR ROLARR). Ann Surg 2021; 274 (06) e1223-e1229
    CrossrefPubMedSearch in Google Scholar
  • 52 Custers PA, van der Sande ME, Grotenhuis BA. et al; Dutch Watch-and-Wait Consortium. Long-term quality of life and functional outcome of patients with rectal cancer following a watch-and-wait approach. JAMA Surg 2023; 158 (05) e230146
    CrossrefPubMedSearch in Google Scholar
  • 53 Somashekhar SP, Krishana A, Goyal D. et al. Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer (CRC). South Asian J Cancer 2024
    Search in Google Scholar
  • 54 Arjona-Sánchez A, Barrios P, Boldo-Roda E. et al. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of hyperthermic intra-peritoneal chemotherapy (HIPEC) with mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer 2018; 18 (01) 183
    CrossrefPubMedSearch in Google Scholar
  • 55 Overman MJ, McDermott R, Leach JL. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18 (09) 1182-1191
    CrossrefPubMedSearch in Google Scholar
  • 56 André T, Shiu KK, Kim TW. et al; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020; 383 (23) 2207-2218
    CrossrefPubMedSearch in Google Scholar
  • 57 Cercek A, Lumish M, Sinopoli J. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022; 386 (25) 2363-2376
    CrossrefPubMedSearch in Google Scholar
  • 58 ClinicalTrials.gov. Durvalumab and Chemoradiation in Treating Patients with Locally Advanced Rectal Cancer. Accessed May 13, 2023 at: https://clinicaltrials.gov/ct2/show/NCT03684135
  • 59 Singh M, Morris VK, Bandey IN, Hong DS, Kopetz S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends Cancer 2024; 10 (07) 598-609
    CrossrefPubMedSearch in Google Scholar
  • 60 Ludford K, Ho WJ, Thomas JV. et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. J Clin Oncol 2023; 41 (12) 2181-2190
    CrossrefPubMedSearch in Google Scholar
  • 61 Xiao WW, Chen G, Gao YH. et al. Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: a randomized clinical trial. Cancer Cell 2024; 42 (09) 1570-1581.e4
    CrossrefPubMedSearch in Google Scholar
  • 62 Farzeen Z, Khan RRM, Chaudhry AR. et al. Dostarlimab: a promising new PD-1 inhibitor for cancer immunotherapy. J Oncol Pharm Pract 2024; 30 (08) 1411-1431
    CrossrefPubMedSearch in Google Scholar
  • 63 Gerard JP, Barbet N, Schiappa R. et al; ICONE group. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2023; 8 (04) 356-367
    CrossrefPubMedSearch in Google Scholar
  • 64 Tissera NS, Esteso F, Luca R. et al. Atypical pattern of response in rectal cancer after neoadjuvant pembrolizumab treatment: a case report, literature review, and proposed management model. J Gastrointest Oncol 2023; 14 (03) 1635-1642
    CrossrefPubMedSearch in Google Scholar
  • 65 Cercek A, Sinopoli JC, Shia J. et al. Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer. J Clin Oncol 2024; 42 (Suppl. 17) LBA3512
    CrossrefSearch in Google Scholar